Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip Mease

Showing results (71-80 of 174) with videos related to

Pageof 18
Sort By:
BMC Rheumatology|September 25, 2021
Ixekizumab improves sleep and work productivity in patients with non-radiographic axial spondyloarthritis: results from the COAST-X trial at 52 weeksAtul Deodhar, Philip Mease, Helena Marzo-Ortega, et al.
Frontiers in Medicine|September 22, 2018
Classification and Outcome Measures for Psoriatic ArthritisYing Ying Leung, Alexis Ogdie, Ana-Maria Orbai, et al.
Rheumatology (Oxford, England)|January 13, 2017
New GRAPPA and EULAR recommendations for the management of psoriatic arthritisLaura C Coates, Laure Gossec, Sofia Ramiro, et al.
Clinical Rheumatology|June 8, 2022
Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year resultsLaura C Coates, Philip Mease, Andris Kronbergs, et al.
European Journal of Rheumatology|August 1, 2019
Comparative effectiveness of secukinumab and etanercept in biologic-naïve patients with psoriatic arthritis assessed by matching-adjusted indirect comparisonPhilip Mease, Ernest Choy, Peter Nash, et al.
Pragmatic and Observational Research|November 2, 2016
Variations in the management of fibromyalgia by physician specialty: rheumatology versus primary careStephen L Able, Rebecca L Robinson, Kurt Kroenke, et al.
Annals of the Rheumatic Diseases|August 7, 2015
A psychometric analysis of outcome measures in peripheral spondyloarthritisMaureen C Turina, Sofia Ramiro, Dominique L Baeten, et al.
Annals of the Rheumatic Diseases|August 7, 2013
Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extensionEdward Keystone, Robert Landewé, Ronald van Vollenhoven, et al.
Arthritis and Rheumatism|June 10, 2004
Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trialJ Peter Kaltwasser, Peter Nash, Dafna Gladman, et al.
Arthritis Research & Therapy|November 14, 2009
Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trialVibeke Strand, Philip Mease, Gerd R Burmester, et al.
Pageof 18

Showing results (71-80 of 174) with videos related to

Sort By:
Pageof 18
BMC Rheumatology|September 25, 2021
Ixekizumab improves sleep and work productivity in patients with non-radiographic axial spondyloarthritis: results from the COAST-X trial at 52 weeksAtul Deodhar, Philip Mease, Helena Marzo-Ortega, et al.
Frontiers in Medicine|September 22, 2018
Classification and Outcome Measures for Psoriatic ArthritisYing Ying Leung, Alexis Ogdie, Ana-Maria Orbai, et al.
Rheumatology (Oxford, England)|January 13, 2017
New GRAPPA and EULAR recommendations for the management of psoriatic arthritisLaura C Coates, Laure Gossec, Sofia Ramiro, et al.
Clinical Rheumatology|June 8, 2022
Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year resultsLaura C Coates, Philip Mease, Andris Kronbergs, et al.
European Journal of Rheumatology|August 1, 2019
Comparative effectiveness of secukinumab and etanercept in biologic-naïve patients with psoriatic arthritis assessed by matching-adjusted indirect comparisonPhilip Mease, Ernest Choy, Peter Nash, et al.
Pragmatic and Observational Research|November 2, 2016
Variations in the management of fibromyalgia by physician specialty: rheumatology versus primary careStephen L Able, Rebecca L Robinson, Kurt Kroenke, et al.
Annals of the Rheumatic Diseases|August 7, 2015
A psychometric analysis of outcome measures in peripheral spondyloarthritisMaureen C Turina, Sofia Ramiro, Dominique L Baeten, et al.
Annals of the Rheumatic Diseases|August 7, 2013
Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extensionEdward Keystone, Robert Landewé, Ronald van Vollenhoven, et al.
Arthritis and Rheumatism|June 10, 2004
Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trialJ Peter Kaltwasser, Peter Nash, Dafna Gladman, et al.
Arthritis Research & Therapy|November 14, 2009
Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trialVibeke Strand, Philip Mease, Gerd R Burmester, et al.
Pageof 18